# Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion

> **NCT07302854** · PHASE2,PHASE3 · RECRUITING · sponsor: **Xiang Luo** · enrollment: 382 (estimated)

## Conditions studied

- Acute Ischemic Stroke
- Medium Vessel Occlusion

## Interventions

- **PROCEDURE:** Intra-arterial Thrombolysis
- **DRUG:** Standard medical treatment

## Key facts

- **NCT ID:** NCT07302854
- **Lead sponsor:** Xiang Luo
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-30
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 382 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07302854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07302854, "Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT07302854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*